Overview

Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

Status:
Completed
Trial end date:
2018-05-18
Target enrollment:
Participant gender:
Summary
This is a single center, prospective, randomized, placebo-controlled study of AG10 in healthy adult subjects
Phase:
Phase 1
Details
Lead Sponsor:
Eidos Therapeutics
Eidos Therapeutics, a BridgeBio company
Collaborator:
Celerion
Treatments:
Coal Tar